| Bioactivity | BIBO3304 TFA is a potent, orally active, and selective neuropeptide Y (NPY) Y1 receptor antagonist, with subnanomolar affinity for both the human and the rat Y1 receptor (IC50=0.38 and 0.72 nM, respectively)[1]. |
| In Vivo | BIBO3304 TFA (30 μg; bilateral paraventricular nucleus injection) attenuates the hyperphagia following fasting[1].BIBO3304 TFA (15-60 μg) dose-dependently inhibits the feeding reponse mediated by 1 μg NPY[1].BIBO3304 TFA (0.5 μM; p.o.) significantly increases serum insulin levels[2]. Animal Model: |
| Name | BIBO3304 TFA |
| CAS | 191868-14-1 |
| Formula | C31H36F3N7O5 |
| Molar Mass | 643.66 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Wieland HA, et al. Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br J Pharmacol. 1998 Oct;125(3):549-55. [2]. Loh K, et al. Inhibition of Y1 receptor signaling improves islet transplant outcome. Nat Commun. 2017 Sep 8;8(1):490. |
BIBO3304 TFA
CAS: 191868-14-1 F: C31H36F3N7O5 W: 643.66
BIBO3304 TFA is a potent, orally active, and selective neuropeptide Y (NPY) Y1 receptor antagonist, with subnanomolar af
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.